Inovio, ApolloBio to Jointly Develop HPV Vaccine in China, Taiwan
News
ApolloBio now enjoys exclusive rights to market Inovio Pharmaceuticals‘ DNA immunotherapy product, VGX-3100, in China and Taiwan under a new collaboration and licensing agreement. The deal allows ApolloBio to develop VGX-3100 as a non-surgical treatment ... Read more